Androxal Approval Status
- FDA approved: No
- Brand name: Androxal
- Generic name: enclomiphene
- Company: Repros Therapeutics Inc.
- Treatment for: Hypogonadism, Male
Androxal (enclomiphene) is a non-steroidal estrogen receptor antagonist under development for the treatment of men of reproductive age with low testosterone levels who want to improve or maintain their fertility and/or sperm function while being treated for low testosterone.
FDA Approval Status for Androxal
|Mar 27, 2013||Repros Reports Both Primary Endpoints Successfully Met in First Pivotal Study of Androxal|
|Feb 8, 2010||Repros Submits Response to FDA Regarding Androxal Indication for Treatment of Hypogonadal Men Wishing to Preserve Fertility|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.